2019 Innovation To Commercialization (I2C) award recipients
The Innovation to Commercialization (I2C) Program is designed to help researchers advance discoveries or inventions towards commercialization by supporting commercialization activities that strengthen the value of their intellectual property, facilitate collaboration and attract future investment.
In its third year, we were pleased to announce nine successful award recipients for the 2019 competition. These researchers are advancing health innovations that range from new nanomedicines for type 2 diabetes; developing a safe and effective analgesic for chronic pain relief; and creating a smart, multifunctional wound dressing for continuous monitoring and treatment of chronic injuries.
Host institution
University of British Columbia
Project title
A GlycoCaged drug delivery system to improve the treatment of inflammatory bowel disease
Read moreHost institution
University of British Columbia
Project title
Novel bioengineered probiotics increase colonization and persistence in the gut enhancing bioavailability and their therapeutic potential for inflammatory bowel disease
Read moreHost institution
University of British Columbia
Project title
Improving cancer immunotherapy using G-CSF-blocking antibodies to overcome myeloid cell-mediated immunosuppression
Read moreHost institution
University of British Columbia
Host institution
University of British Columbia
Project title
Novel nanomedicines for resolving inflammation as a treatment for type 2 diabetes
Read moreHost institution
University of Victoria
Project title
A smart multifunctional wound dressing for continuous monitoring and treatment of chronic injuries
Read moreTeam members
Host institution
University of British Columbia
Host institution
University of British Columbia
Project title
Biomarker tests to diagnose and prognose acute exacerbations of chronic obstructive pulmonary disease
Read moreTeam members
Host institution
University of Victoria
Partner(s)
Pacific Parkinson's Research Institute